Sun Pharmaceutical Industries Ltd (SUN.BO)
|Market Cap (Mil.):||Rs1,550,991.00|
|Shares Outstanding (Mil.):||2,071.16|
MUMBAI, July 16 - Sun Pharmaceutical Industries Ltd, India's third-largest generic drugmaker by sales, said on Wednesday it had acquired U.S.-based Pharmalucence Inc, which has sterile injectable capacity and research capabilities.
* BSE index gains 0.15 pct; NSE ends 0.21 pct higher * Century Textile rallies after investor Damani buys stake * Aban likely to launch up to $150 mln share sale on Friday - sources * Ranbaxy gets FDA approval for Novartis's Diovan generic By Abhishek Vishnoi MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained
* Compares with analysts' forecast for 958.7 mln in profit
MUMBAI, May 9 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by rival Sun Pharmaceutical Industries Ltd for $3.2 billion, posted a surprise loss in the March quarter due to write-offs related to regulatory sanctions for poor manufacturing quality.
(Adds item on Freshpet LLC, El Pollo Loco Inc, Sun Pharmaceutical Industries Ltd, Go Daddy Group)
MUMBAI - India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States, after completing a $3.2 billion takeover of its loss-making rival by the year end, sources with direct knowledge of the matter said.
Sun Pharmaceutical Industries Ltd (Sun Pharma) & Ranbaxy Laboratories Ltd (Ranbaxy)
April 7 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:
(Corrects first and last paragraphs to say Dilip Shanghvi is managing director, not chairman of Sun Pharma)
MUMBAI - Shares in India's Ranbaxy Laboratories Ltd fell as much as 3.2 percent on profit-taking after Sun Pharmaceutical Industries Ltd said it will buy the company in a $3.2 billion all-share deal, creating the world's fifth-largest generic drug maker.
Earnings vs. Estimates
Analyst Research Reports
Provider: Wright Reports
Provider: Thomson Reuters Stock Report
Sun Pharmaceutical Industries Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Sun Pharmaceutical Industries Ltd (524715) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratios and Financial Averages
Provider: Plunkett Research, Ltd.
Provider: BuySellSignals Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.